1
|
Rastogi SK, Ciliberto VC, Trevino MZ, Campbell BA, Brittain WJ. Green Approach Toward Triazole Forming Reactions for Developing Anticancer Drugs. Curr Org Synth 2024; 21:380-420. [PMID: 37157212 DOI: 10.2174/1570179420666230508125144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Revised: 03/01/2023] [Accepted: 03/15/2023] [Indexed: 05/10/2023]
Abstract
Compounds containing triazole have many significant applications in the dye and ink industry, corrosion inhibitors, polymers, and pharmaceutical industries. These compounds possess many antimicrobial, antioxidant, anticancer, antiviral, anti-HIV, antitubercular, and anticancer activities. Several synthetic methods have been reported for reducing time, minimizing synthetic steps, and utilizing less hazardous and toxic solvents and reagents to improve the yield of triazoles and their analogues synthesis. Among the improvement in methods, green approaches towards triazole forming biologically active compounds, especially anticancer compounds, would be very important for pharmaceutical industries as well as global research community. In this article, we have reviewed the last five years of green chemistry approaches on click reaction between alkyl azide and alkynes to install 1,2,3-triazole moiety in natural products and synthetic drug-like molecules, such as in colchicine, flavanone cardanol, bisphosphonates, thiabendazoles, piperazine, prostanoid, flavonoid, quinoxalines, C-azanucleoside, dibenzylamine, and aryl-azotriazole. The cytotoxicity of triazole hybrid analogues was evaluated against a panel of cancer cell lines, including multidrug-resistant cell lines.
Collapse
Affiliation(s)
- Shiva K Rastogi
- Department of Chemistry and Biochemistry, Texas State University, 601 University Drive, San Marcos, TX, 78666, USA
| | - Veronica C Ciliberto
- Department of Chemistry and Biochemistry, Texas State University, 601 University Drive, San Marcos, TX, 78666, USA
| | - Monica Z Trevino
- Department of Chemistry and Biochemistry, Texas State University, 601 University Drive, San Marcos, TX, 78666, USA
| | - Brooke A Campbell
- Department of Chemistry and Biochemistry, Texas State University, 601 University Drive, San Marcos, TX, 78666, USA
| | - William J Brittain
- Department of Chemistry and Biochemistry, Texas State University, 601 University Drive, San Marcos, TX, 78666, USA
| |
Collapse
|
2
|
Shi XY, Jiao H, Zhang JK, Tian XY, Guo DF, Gao J, Jia MQ, Song J, Zhang SY, Fu XJ, Tang HW. Discovery of novel arylamide derivatives containing piperazine moiety as inhibitors of tubulin polymerisation with potent liver cancer inhibitory activity. J Enzyme Inhib Med Chem 2023; 38:2237701. [PMID: 37489043 PMCID: PMC10392279 DOI: 10.1080/14756366.2023.2237701] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 06/17/2023] [Accepted: 07/12/2023] [Indexed: 07/26/2023] Open
Abstract
In this work, a series of novel arylamide derivatives containing piperazine moiety were designed and synthesised as tubulin polymerisation inhibitors. Among 25 target compounds, compound 16f (MY-1121) exhibited low nanomolar IC50 values ranging from 0.089 to 0.238 μM against nine human cancer cells. Its inhibitory effects on liver cancer cells were particularly evident with IC50 values of 89.42 and 91.62 nM for SMMC-7721 and HuH-7 cells, respectively. Further mechanism studies demonstrated that compound 16f (MY-1121) could bind to the colchicine binding site of β-tubulin and directly act on β-tubulin, thus inhibiting tubulin polymerisation. Additionally, compound 16f (MY-1121) could inhibit colony forming ability, cause morphological changes, block cell cycle arrest at the G2 phase, induce cell apoptosis, and regulate the expression of cell cycle and cell apoptosis related proteins in liver cancer cells. Overall, the promising bioactivities of compound 16f (MY-1121) make the novel arylamide derivatives have the value for further development as tubulin polymerisation inhibitors with potent anticancer activities.
Collapse
Affiliation(s)
- Xiao-Yi Shi
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Huang Jiao
- School of Pharmaceutical Sciences, Institute of Drug Discovery & Development, Key Laboratory of Advanced Drug Preparation Technologies (Ministry of Education), Zhengzhou University, Zhengzhou, China
| | - Jia-Kai Zhang
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Xin-Yi Tian
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Dan-Feng Guo
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Jie Gao
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Mei-Qi Jia
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Jian Song
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Sai-Yang Zhang
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Xiang-Jing Fu
- School of Pharmaceutical Sciences, Institute of Drug Discovery & Development, Key Laboratory of Advanced Drug Preparation Technologies (Ministry of Education), Zhengzhou University, Zhengzhou, China
| | - Hong-Wei Tang
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| |
Collapse
|
3
|
Discovery of Simple Diacylhydrazine-Functionalized Cinnamic Acid Derivatives as Potential Microtubule Stabilizers. Int J Mol Sci 2022; 23:ijms232012365. [PMID: 36293224 PMCID: PMC9604255 DOI: 10.3390/ijms232012365] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2022] [Revised: 09/21/2022] [Accepted: 10/05/2022] [Indexed: 11/04/2022] Open
Abstract
To develop novel microtubule-binding agents for cancer therapy, an array of N-cinnamoyl-N'-(substituted)acryloyl hydrazide derivatives were facilely synthesized through a two-step process. Initially, the antiproliferative activity of these title compounds was explored against A549, 98 PC-3 and HepG2 cancer cell lines. Notably, compound I23 exhibited the best antiproliferative activity against three cancer lines with IC50 values ranging from 3.36 to 5.99 μM and concurrently afforded a lower cytotoxicity towards the NRK-52E cells. Anticancer mechanism investigations suggested that the highly bioactive compound I23 could potentially promote the protofilament assembly of tubulin, thus eventually leading to the stagnation of the G2/M phase cell cycle of HepG2 cells. Moreover, compound I23 also disrupted cancer cell migration and significantly induced HepG2 cells apoptosis in a dosage-dependent manner. Additionally, the in silico analysis indicated that compound I23 exhibited an acceptable pharmacokinetic profile. Overall, these easily prepared N-cinnamoyl-N'-(substituted)acryloyl hydrazide derivatives could serve as potential microtubule-interacting agents, probably as novel microtubule-stabilizers.
Collapse
|
4
|
Debnath S, Sarkar A, Mukherjee DD, Ray S, Mahata B, Mahata T, Parida PK, Das T, Mukhopadhyay R, Ghosh Z, Biswas K. Eriodictyol mediated selective targeting of the TNFR1/FADD/TRADD axis in cancer cells induce apoptosis and inhibit tumor progression and metastasis. Transl Oncol 2022; 21:101433. [PMID: 35462210 PMCID: PMC9046888 DOI: 10.1016/j.tranon.2022.101433] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 04/11/2022] [Accepted: 04/11/2022] [Indexed: 12/03/2022] Open
Abstract
Eriodictyol induces Selective Cytotoxicity to tumor cells. Eriodictyol enhances TNFR1 expression in cancer cells. Eriodictyol targets TNFR1 to selectively mediate apoptosis and cytotoxicity to cancer cells. Eriodictyol reduces tumour burden in experimentally induced lung metastasis in vivo.
While the anti-inflammatory activities of Eriodictyol, a plant-derived flavonoid is well-known, reports on its anti-cancer efficacy and selective cytotoxicity in cancer cells are still emerging. However, little is known regarding its mechanism of selective anti-cancer activities. Here, we show the mechanism of selective cytotoxicity of Eriodictyol towards cancer cells compared to normal cells. Investigation reveals that Eriodictyol significantly upregulates TNFR1 expression in tumor cells (HeLa and SK-RC-45) while sparing the normal cells (HEK, NKE and WI-38), which display negligible TNFR1 expression, irrespective of the absence or presence of Eriodictyol. Further investigation of the molecular events reveal that Eriodictyol induces apoptosis through expression of the pro-apoptotic DISC components leading to activation of the caspase cascade. In addition, CRISPR-Cas9 mediated knockout of TNFR1 completely blocks apoptosis in HeLa cells in response to Eriodictyol, confirming that Eriodictyol induced cancer cell apoptosis is indeed TNFR1-dependent. Finally, in vivo data demonstrates that Eriodictyol not only impedes tumor growth and progression, but also inhibits metastasis in mice implanted with 4T1 breast cancer cells. Thus, our study has identified Eriodictyol as a compound with high selectivity towards cancer cells through TNFR1 and suggests that it can be further explored for its prospect in cancer therapeutics.
Collapse
|
5
|
Ebenezer O, Shapi M, Tuszynski JA. A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization. Int J Mol Sci 2022; 23:4001. [PMID: 35409361 PMCID: PMC8999808 DOI: 10.3390/ijms23074001] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 03/17/2022] [Accepted: 03/29/2022] [Indexed: 12/17/2022] Open
Abstract
Microtubules are cylindrical protein polymers formed from αβ-tubulin heterodimers in the cytoplasm of eukaryotic cells. Microtubule disturbance may cause cell cycle arrest in the G2/M phase, and anomalous mitotic spindles will form. Microtubules are an important target for cancer drug action because of their critical role in mitosis. Several microtubule-targeting agents with vast therapeutic advantages have been developed, but they often lead to multidrug resistance and adverse side effects. Thus, single-target therapy has drawbacks in the effective control of tubulin polymerization. Molecular hybridization, based on the amalgamation of two or more pharmacophores of bioactive conjugates to engender a single molecular structure with enhanced pharmacokinetics and biological activity, compared to their parent molecules, has recently become a promising approach in drug development. The practical application of combined active scaffolds targeting tubulin polymerization inhibitors has been corroborated in the past few years. Meanwhile, different designs and syntheses of novel anti-tubulin hybrids have been broadly studied, illustrated, and detailed in the literature. This review describes various molecular hybrids with their reported structural-activity relationships (SARs) where it is possible in an effort to generate efficacious tubulin polymerization inhibitors. The aim is to create a platform on which new active scaffolds can be modeled for improved tubulin polymerization inhibitory potency and hence, the development of new therapeutic agents against cancer.
Collapse
Affiliation(s)
- Oluwakemi Ebenezer
- Department of Chemistry, Faculty of Natural Science, Mangosuthu University of Technology, Umlazi 4031, South Africa; (O.E.); (M.S.)
| | - Michael Shapi
- Department of Chemistry, Faculty of Natural Science, Mangosuthu University of Technology, Umlazi 4031, South Africa; (O.E.); (M.S.)
| | - Jack A. Tuszynski
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada
- Department of Physics, University of Alberta, Edmonton, AB T6G 2E1, Canada
- DIMEAS, Politecnico di Torino, 10129 Turin, Italy
| |
Collapse
|
6
|
Zhou X, Liu J, Meng J, Fu Y, Wu Z, Ouyang G, Wang Z. Discovery of facile amides-functionalized rhodanine-3-acetic acid derivatives as potential anticancer agents by disrupting microtubule dynamics. J Enzyme Inhib Med Chem 2021; 36:1996-2009. [PMID: 34525898 PMCID: PMC8451688 DOI: 10.1080/14756366.2021.1975695] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Microtubule dynamics are crucial for multiple cell functions, and cancer cells are particularly sensitive to microtubule-modulating agents. Here, we describe the design and synthesis of a series of (Z)-2-(5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)-N-phenylacetamide derivatives and evaluation of their microtubule-modulating and anticancer activities in vitro. Proliferation assays identified I20 as the most potent of the antiproliferative compounds, with 50% inhibitory concentrations ranging from 7.0 to 20.3 µM with A549, PC-3, and HepG2 human cancer cell lines. Compound I20 also disrupted cancer A549 cell migration in a concentration-dependent manner. Immunofluorescence microscopy, transmission electron microscopy, and tubulin polymerisation assays suggested that compound I20 promoted protofilament assembly. In support of this possibility, computational docking studies revealed a strong interaction between compound I20 and tubulin Arg β369, which is also the binding site for the anticancer drug Taxol. Our results suggest that (Z)-2-(5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)-N-phenylacetamide derivatives could have utility for the development of microtubule-stabilising therapeutic agents.
Collapse
Affiliation(s)
- Xiang Zhou
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guiyang, People's Republic of China.,College of Pharmacy, Guizhou University, Guiyang, People's Republic of China
| | - Jiamin Liu
- College of Pharmacy, Guizhou University, Guiyang, People's Republic of China
| | - Jiao Meng
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guiyang, People's Republic of China
| | - Yihong Fu
- College of Pharmacy, Guizhou University, Guiyang, People's Republic of China
| | - Zhibin Wu
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guiyang, People's Republic of China
| | - Guiping Ouyang
- College of Pharmacy, Guizhou University, Guiyang, People's Republic of China
| | - Zhenchao Wang
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guiyang, People's Republic of China.,College of Pharmacy, Guizhou University, Guiyang, People's Republic of China
| |
Collapse
|
7
|
Barros CS, Bossing T. Microtubule disruption upon CNS damage triggers mitotic entry via TNF signaling activation. Cell Rep 2021; 36:109325. [PMID: 34233183 DOI: 10.1016/j.celrep.2021.109325] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 11/12/2020] [Accepted: 06/08/2021] [Indexed: 01/15/2023] Open
Abstract
Repair after traumatic injury often starts with mitotic activation around the lesion edges. Early midline cells in the Drosophila embryonic CNS can enter into division following the traumatic disruption of microtubules. We demonstrate that microtubule disruption activates non-canonical TNF signaling by phosphorylation of TGF-β activated kinase 1 (Tak1) and its target IkappaB kinase (Ik2), culminating in Dorsal/NfkappaB nuclear translocation and Jra/Jun expression. Tak1 and Ik2 are necessary for the damaged-induced divisions. Microtubule disruption caused by Tau accumulation is also reported in Alzheimer's disease (AD). Human Tau expression in Drosophila midline cells is sufficient to induce Tak1 phosphorylation, Dorsal and Jra/Jun expression, and entry into mitosis. Interestingly, activation of Tak1 and Tank binding kinase 1 (Tbk1), the human Ik2 ortholog, and NfkappaB upregulation are observed in AD brains.
Collapse
Affiliation(s)
- Claudia S Barros
- Peninsula Medical School, Faculty of Health, University of Plymouth, John Bull Building, 16 Research Way, Plymouth PL6 8BU, UK
| | - Torsten Bossing
- Peninsula Medical School, Faculty of Health, University of Plymouth, John Bull Building, 16 Research Way, Plymouth PL6 8BU, UK.
| |
Collapse
|
8
|
Manasa KL, Thatikonda S, Sigalapalli DK, Vuppaladadium S, Devi GP, Godugu C, Alvala M, Nagesh N, Babu BN. Design and synthesis of substituted (1-(benzyl)-1 H-1,2,3-triazol-4-yl)(piperazin-1-yl)methanone conjugates: study on their apoptosis inducing ability and tubulin polymerization inhibition. RSC Med Chem 2020; 11:1295-1302. [PMID: 34095841 PMCID: PMC8126877 DOI: 10.1039/d0md00162g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 07/29/2020] [Indexed: 12/20/2022] Open
Abstract
A library of substituted (1-(benzyl)-1H-1,2,3-triazol-4-yl)(piperazin-1-yl)methanone derivatives were designed, synthesized and screened for their in vitro cytotoxic activity against BT-474, HeLa, MCF-7, NCI-H460 and HaCaT cells by employing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Among all the synthesized analogues, compound 10ec displayed the highest cytotoxicity with the IC50 value of 0.99 ± 0.01 μM towards BT-474 cancer cell line. The target compound (10ec) was also evaluated for its tubulin polymerization inhibition study. Detailed biological studies such as acridine orange/ethidium bromide (AO/EB), DAPI and annexin V-FITC/propidium iodide staining assay suggested that compound 10ec induced the apoptosis of BT-474 cells. The clonogenic assay revealed that the inhibition of colony formation in BT-474 cells by 10ec in concentration-dependent manner. Moreover, the flow cytometric analysis revealed that 10ec induced apoptosis via cell cycle arrest at the sub-G1 and G2/M phase. In silico studies of sulfonyl piperazine-integrated triazole conjugates unveil that they possess drug-like properties. According to the molecular modelling studies, compound 10ec binds to the colchicine binding site of the tubulin.
Collapse
Affiliation(s)
- Kesari Lakshmi Manasa
- Department of Fluoro-Agrochemicals, CSIR-Indian Institute of Chemical Technology Hyderabad-500007 India
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Hyderabad-500037 India
| | - Sowjanya Thatikonda
- Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India
| | - Dilep Kumar Sigalapalli
- Department of Fluoro-Agrochemicals, CSIR-Indian Institute of Chemical Technology Hyderabad-500007 India
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Hyderabad-500037 India
| | | | - Ganthala Parimala Devi
- Department of Fluoro-Agrochemicals, CSIR-Indian Institute of Chemical Technology Hyderabad-500007 India
| | - Chandraiah Godugu
- Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad-500037 India
| | - Mallika Alvala
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Hyderabad-500037 India
| | - Narayana Nagesh
- CSIR-Centre for Cellular and Molecular Biology Hyderabad 500007 India
| | - Bathini Nagendra Babu
- Department of Fluoro-Agrochemicals, CSIR-Indian Institute of Chemical Technology Hyderabad-500007 India
| |
Collapse
|
9
|
Lakshmi Manasa K, Thatikonda S, Sigalapalli DK, Sagar A, Kiranmai G, Kalle AM, Alvala M, Godugu C, Nagesh N, Nagendra Babu B. Design and synthesis of β-carboline linked aryl sulfonyl piperazine derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability. Bioorg Chem 2020; 101:103983. [DOI: 10.1016/j.bioorg.2020.103983] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Revised: 04/15/2020] [Accepted: 05/29/2020] [Indexed: 12/26/2022]
|
10
|
Drug Repositioning of the α 1-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug? Int J Mol Sci 2020; 21:ijms21155339. [PMID: 32727149 PMCID: PMC7432507 DOI: 10.3390/ijms21155339] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 07/22/2020] [Accepted: 07/25/2020] [Indexed: 12/16/2022] Open
Abstract
Failure of conventional treatments is often observed in cancer management and this requires the development of alternative therapeutic strategies. However, new drug development is known to be a high-failure process because of the possibility of a lower efficacy than expected for the drug or appearance of non-manageable side effects. Another way to find alternative therapeutic drugs consists in identifying new applications for drugs already approved for a particular disease: a concept named "drug repurposing". In this context, several studies demonstrated the potential anti-tumour activity exerted by α1-adrenergic receptor antagonists and notably renewed interest for naftopidil as an anti-cancer drug. Naftopidil is used for benign prostatic hyperplasia management in Japan and a retrospective study brought out a reduced incidence of prostate cancer in patients that had been prescribed this drug. Further studies showed that naftopidil exerted anti-proliferative and cytotoxic effects on prostate cancer as well as several other cancer types in vitro, as well as ex vivo and in vivo. Moreover, naftopidil was demonstrated to modulate the expression of Bcl-2 family pro-apoptotic members which could be used to sensitise cancer cells to targeting therapies and to overcome resistance of cancer cells to apoptosis. For most of these anti-cancer effects, the molecular pathway is either not fully deciphered or shown to involve α1-adrenergic receptor-independent pathway, suggesting off target transduction signals. In order to improve its efficacy, naftopidil analogues were designed and shown to be effective in several studies. Thereby, naftopidil appears to display anti-cancer properties on different cancer types and could be considered as a candidate for drug repurposing although its anti-cancerous activities need to be studied more deeply in prospective randomized clinical trials.
Collapse
|
11
|
Laudisi F, Marônek M, Di Grazia A, Monteleone G, Stolfi C. Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System. Int J Mol Sci 2020; 21:ijms21144957. [PMID: 32668817 PMCID: PMC7404055 DOI: 10.3390/ijms21144957] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 07/10/2020] [Accepted: 07/12/2020] [Indexed: 12/20/2022] Open
Abstract
Tumors of the digestive system, when combined together, account for more new cases and deaths per year than tumors arising in any other system of the body and their incidence continues to increase. Despite major efforts aimed at discovering and validating novel and effective drugs against these malignancies, the process of developing such drugs remains lengthy and costly, with high attrition rates. Drug repositioning (also known as drug repurposing), that is, the process of finding new uses for approved drugs, has been gaining popularity in oncological drug development as it provides the opportunity to expedite promising anti-cancer agents into clinical trials. Among the drugs considered for repurposing in oncology, compounds belonging to some classes of anthelmintics—a group of agents acting against infections caused by parasitic worms (helminths) that colonize the mammalian intestine—have shown pronounced anti-tumor activities and attracted particular attention due to their ability to target key oncogenic signal transduction pathways. In this review, we summarize and discuss the available experimental and clinical evidence about the use of anthelmintic drugs for the treatment of cancers of the digestive system.
Collapse
Affiliation(s)
- Federica Laudisi
- Department of Systems Medicine, University of “Tor Vergata”, 00133 Rome, Italy; (F.L.); (A.D.G.); (G.M.)
| | - Martin Marônek
- Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia;
| | - Antonio Di Grazia
- Department of Systems Medicine, University of “Tor Vergata”, 00133 Rome, Italy; (F.L.); (A.D.G.); (G.M.)
| | - Giovanni Monteleone
- Department of Systems Medicine, University of “Tor Vergata”, 00133 Rome, Italy; (F.L.); (A.D.G.); (G.M.)
| | - Carmine Stolfi
- Department of Systems Medicine, University of “Tor Vergata”, 00133 Rome, Italy; (F.L.); (A.D.G.); (G.M.)
- Division of Clinical Biochemistry and Clinical Molecular Biology, University of Rome “Tor Vergata”, 00133 Rome, Italy
- Correspondence: ; Tel.: +39-06-72596163
| |
Collapse
|
12
|
Wang C, Li Y, Liu T, Wang Z, Zhang Y, Bao K, Wu Y, Guan Q, Zuo D, Zhang W. Design, synthesis and evaluation of antiproliferative and antitubulin activities of 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4H-1,2,4-triazoles. Bioorg Chem 2020; 104:103909. [PMID: 33142419 DOI: 10.1016/j.bioorg.2020.103909] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2020] [Revised: 03/27/2020] [Accepted: 04/30/2020] [Indexed: 01/01/2023]
Abstract
A series of novel 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4H-1,2,4-triazoles possessing 1,2,4-triazole as the hydrogen-bond acceptor were designed, synthesized and evaluated for their antiproliferative and tubulin polymerization inhibitory activities. Some of them exhibited moderate activities in vitro against the three cancer cell lines including SGC-7901, A549 and HeLa. Compound 6e exhibited the highest potency against the three cancer cell lines. Moreover, the tubulin polymerization experiments indicated that compound 6e could inhibit the tubulin polymerization. Immunofluorescence study and cell cycle analysis clearly revealed compound 6e could disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. In addition, molecular docking analysis demonstrated the interaction of compound 6e at the colchicine-binding site of tubulin. These preliminary results suggested that compound 6e is a new colchicine binding site inhibitor and worthy of further investigation.
Collapse
Affiliation(s)
- Chao Wang
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Yuelin Li
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Tong Liu
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Zeyu Wang
- Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Yujing Zhang
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Kai Bao
- Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Yingliang Wu
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China
| | - Qi Guan
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
| | - Daiying Zuo
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
| | - Weige Zhang
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
| |
Collapse
|
13
|
Nadaf AQA, Najare MS, Garbhagudi M, Mantur S, Sunagar MG, Gaonkar S, Joshi S, Khazi IAM. Synthesis of 6‐[4‐(4‐Propoxyphenyl)piperazin‐1‐yl]‐9
H
‐purine Derivatives as Antimycobacterial and Antifungal Agents:
In Vitro
Evaluation and
In Silico
Study. Chem Biodivers 2020; 17:e2000053. [DOI: 10.1002/cbdv.202000053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Accepted: 03/12/2020] [Indexed: 11/07/2022]
Affiliation(s)
| | - Mahesh S. Najare
- Department of ChemistryKarnatak University Dharwad 580003 Karnataka India
| | | | - Shivaraj Mantur
- Department of ChemistryKarnatak University Dharwad 580003 Karnataka India
| | | | - Supreet Gaonkar
- Department of ChemistryKarnatak University Dharwad 580003 Karnataka India
| | - Shrinivas Joshi
- Novel Drug Design and Discovery LaboratoryDepartment of Pharmaceutical ChemistryS.E.T.'s College of Pharmacy, Sangolli Rayanna Nagar Dharwad 580002 Karnataka India
| | | |
Collapse
|
14
|
Jadala C, Sathish M, Anchi P, Tokala R, Lakshmi UJ, Reddy VG, Shankaraiah N, Godugu C, Kamal A. Synthesis of Combretastatin‐A4 Carboxamidest that Mimic Sulfonyl Piperazines by a Molecular Hybridization Approach:
in vitro
Cytotoxicity Evaluation and Inhibition of Tubulin Polymerization. ChemMedChem 2019; 14:2052-2060. [DOI: 10.1002/cmdc.201900541] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 10/15/2019] [Indexed: 01/08/2023]
Affiliation(s)
- Chetna Jadala
- Department of Medicinal ChemistryNational Institute of Pharmaceutical Education and Research (NIPER) Hyderabad 500037 India
| | - Manda Sathish
- Medicinal Chemistry and PharmacologyCSIR-Indian Institute of Chemical Technology Hyderabad 500007 India
| | - Pratibha Anchi
- Department of Regulatory ToxicologyNational Institute of Pharmaceutical Education and Research (NIPER) Hyderabad 500037 India
| | - Ramya Tokala
- Department of Medicinal ChemistryNational Institute of Pharmaceutical Education and Research (NIPER) Hyderabad 500037 India
| | - Uppu Jaya Lakshmi
- Department of Medicinal ChemistryNational Institute of Pharmaceutical Education and Research (NIPER) Hyderabad 500037 India
| | - Velma Ganga Reddy
- Medicinal Chemistry and PharmacologyCSIR-Indian Institute of Chemical Technology Hyderabad 500007 India
| | - Nagula Shankaraiah
- Department of Medicinal ChemistryNational Institute of Pharmaceutical Education and Research (NIPER) Hyderabad 500037 India
| | - Chandraiah Godugu
- Department of Regulatory ToxicologyNational Institute of Pharmaceutical Education and Research (NIPER) Hyderabad 500037 India
| | - Ahmed Kamal
- Medicinal Chemistry and PharmacologyCSIR-Indian Institute of Chemical Technology Hyderabad 500007 India
- School of Pharmaceutical Education and Research (SPER) Jamia Hamdard New Delhi 110062 India
| |
Collapse
|
15
|
The effect and mechanism of millepachine-disrupted spindle assembly in tumor cells. Anticancer Drugs 2019; 29:449-456. [PMID: 29649038 DOI: 10.1097/cad.0000000000000618] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Millepachine (MIL) is a bioactive natural product that shows great potential for cancer treatment. Previous studies showed that MIL was a novel cancer drug candidate with a special structure. To provide reference for the research and development of MIL, we further investigated the mechanism of MIL inducing G2/M arrest and found MIL disrupted spindle assembly in tumor cells. In this study, we investigated the disrupting spindle assembly effects of MIL with a focus on its potential mechanism of action. First, we indicated that MIL did not inhibit microtubule polymerization from the results of in-vivo microtubule nucleation assay and microtubule polymerization in-vitro assay but delayed this process by inhibiting the production of ATP in tumor cells. Thereafter, we investigated the effect of MIL on the mitotic spindle. We found that MIL induced multipolar spindles by inhibiting the activity of Eg5 and inhibited mitotic spindle formation and chromatin condensation by the activation of the spindle assembly checkpoint (SAC) in tumor cells. These results established a novel function of MIL in regulating the assembly of mitotic spindle. As Eg5 and SAC are antitumor targets, effect of MIL on the Eg5 protein and SAC activation hinted that MIL has novel application in the development of antitumor drugs.
Collapse
|
16
|
Arnst KE, Banerjee S, Chen H, Deng S, Hwang DJ, Li W, Miller DD. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Med Res Rev 2019; 39:1398-1426. [PMID: 30746734 DOI: 10.1002/med.21568] [Citation(s) in RCA: 89] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 01/16/2019] [Accepted: 01/19/2019] [Indexed: 12/25/2022]
Abstract
Microtubule (MT)-targeting agents are highly successful drugs as chemotherapeutic agents, and this is attributed to their ability to target MT dynamics and interfere with critical cellular functions, including, mitosis, cell signaling, intracellular trafficking, and angiogenesis. Because MT dynamics vary in the different stages of the cell cycle, these drugs tend to be the most effective against mitotic cells. While this class of drug has proven to be effective against many cancer types, significant hurdles still exist and include overcoming aspects such as dose limited toxicities and the development of resistance. Newer generations of developed drugs attack these problems and alternative approaches such as the development of dual tubulin and kinase inhibitors are being investigated. This approach offers the potential to show increased efficacy and lower toxicities. This review covers different categories of MT-targeting agents, recent advances in dual inhibitors, and current challenges for this drug target.
Collapse
Affiliation(s)
- Kinsie E Arnst
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Souvik Banerjee
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Hao Chen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Shanshan Deng
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Dong-Jin Hwang
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Wei Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Duane D Miller
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee
| |
Collapse
|
17
|
Narva S, Chitti S, Amaroju S, Goud S, Alvala M, Bhattacharjee D, Jain N, Kondapalli Venkata Gowri CS. Design, Synthesis, and Biological Evaluation of 2-(4-Aminophenyl)benzothiazole Analogues as Antiproliferative Agents. J Heterocycl Chem 2018. [DOI: 10.1002/jhet.3427] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Suresh Narva
- Department of Chemistry; Birla Institute of Technology and Science; Pilani, Hyderabad Campus, Jawahar Nagar Hyderabad 500078 Telangana India
| | - Surendar Chitti
- Department of Chemistry; Birla Institute of Technology and Science; Pilani, Hyderabad Campus, Jawahar Nagar Hyderabad 500078 Telangana India
| | - Suresh Amaroju
- Department of Chemistry; Birla Institute of Technology and Science; Pilani, Hyderabad Campus, Jawahar Nagar Hyderabad 500078 Telangana India
| | - Sridhar Goud
- National Institute of Pharmaceutical Education and Research-Hyderabad; Hyderabad 500037 Telangana India
| | - Mallika Alvala
- National Institute of Pharmaceutical Education and Research-Hyderabad; Hyderabad 500037 Telangana India
| | - Debanjan Bhattacharjee
- Centre for Chemical Biology; CSIR-Indian Institute of Chemical Technology; Tarnaka Hyderabad 500007 Telangana India
| | - Nishant Jain
- Centre for Chemical Biology; CSIR-Indian Institute of Chemical Technology; Tarnaka Hyderabad 500007 Telangana India
| | | |
Collapse
|
18
|
Sato-Kaneko F, Wang X, Yao S, Hosoya T, Lao FS, Messer K, Pu M, Shukla NM, Cottam HB, Chan M, Carson DA, Corr M, Hayashi T. Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy. BIOMED RESEARCH INTERNATIONAL 2018; 2018:8091283. [PMID: 30406141 PMCID: PMC6199861 DOI: 10.1155/2018/8091283] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 09/17/2018] [Indexed: 12/26/2022]
Abstract
For an activating immunotherapy such as adjuvants, a compound that can prolong immune stimulation may enhance efficacy. We leveraged data from two prior high throughput screens with NF-κB and interferon reporter cell lines to identify 4H-chromene-3-carbonitriles as a class of compounds that prolonged activation in both screens. We repurchased 23 of the most promising candidates. Out of these compounds we found #1 to be the most effective agent in stimulating the release of cytokines and chemokines from immune cells, including murine primary bone marrow derived dendritic cells. Mechanistically, #1 inhibited tubulin polymerization, and its effect on immune cell activation was abolished in cells mutated in the beta-tubulin gene (TUBB) encoding the site where colchicine binds. Treatment with #1 resulted in mitochondrial depolarization followed by mitogen-activated protein kinase activation. Because tubulin polymerization modulating agents have been used for chemotherapy to treat malignancy and #1 activated cytokine responses, we hypothesized that #1 could be effective for cancer immunotherapy. Intratumoral injection of #1 delayed tumor growth in a murine syngeneic model of head and neck cancer. When combined with PD-1 blockade, tumor growth slowed in the injected tumor nodule and there was an abscopal effect in an uninjected nodule on the contralateral flank, suggesting central antitumor immune activation. Thus, we identified a new class of tubulin depolymerizing agent that acts as both an innate and an adaptive immune activating agent and that limits solid tumor growth when used concurrently with a checkpoint inhibitor.
Collapse
Affiliation(s)
- Fumi Sato-Kaneko
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Xiaodong Wang
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
- School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Nanhai Ave 3688, Shenzhen, Guangdong 518060, China
| | - Shiyin Yao
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Tadashi Hosoya
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Fitzgerald S. Lao
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Karen Messer
- Division of Biostatistics, University of California San Diego, La Jolla 92093, USA
| | - Minya Pu
- Division of Biostatistics, University of California San Diego, La Jolla 92093, USA
| | - Nikunj M. Shukla
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Howard B. Cottam
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Michael Chan
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Dennis A. Carson
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| | - Maripat Corr
- Department of Medicine, University of California San Diego, La Jolla 92093, USA
| | - Tomoko Hayashi
- Moores Cancer Center, University of California San Diego, La Jolla 92093, USA
| |
Collapse
|
19
|
Bond MJ, Bleiler M, Harrison LE, Scocchera EW, Nakanishi M, G-Dayanan N, Keshipeddy S, Rosenberg DW, Wright DL, Giardina C. Spindle Assembly Disruption and Cancer Cell Apoptosis with a CLTC-Binding Compound. Mol Cancer Res 2018; 16:1361-1372. [PMID: 29769406 DOI: 10.1158/1541-7786.mcr-18-0178] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 04/05/2018] [Accepted: 04/25/2018] [Indexed: 11/16/2022]
Abstract
AK3 compounds are mitotic arrest agents that induce high levels of γH2AX during mitosis and apoptosis following release from arrest. We synthesized a potent AK3 derivative, AK306, that induced arrest and apoptosis of the HCT116 colon cancer cell line with an EC50 of approximately 50 nmol/L. AK306 was active on a broad spectrum of cancer cell lines with total growth inhibition values ranging from approximately 25 nmol/L to 25 μmol/L. Using biotin and BODIPY-linked derivatives of AK306, binding to clathrin heavy chain (CLTC/CHC) was observed, a protein with roles in endocytosis and mitosis. AK306 inhibited mitosis and endocytosis, while disrupting CHC cellular localization. Cells arrested in mitosis by AK306 showed the formation of multiple microtubule-organizing centers consisting of pericentrin, γ-tubulin, and Aurora A foci, without apparent centrosome amplification. Cells released from AK306 arrest were unable to form bipolar spindles, unlike nocodazole-released cells that reformed spindles and completed division. Like AK306, CHC siRNA knockdown disrupted spindle formation and activated p53. A short-term (3-day) treatment of tumor-bearing APC-mutant mice with AK306 increased apoptosis in tumors, but not normal mucosa. These findings indicate that targeting the mitotic CHC complex can selectively induce apoptosis and may have therapeutic value.Implication: Disruption of clathrin with a small-molecule inhibitor, AK306, selectively induces apoptosis in cancer cells by disrupting bipolar spindle formation. Mol Cancer Res; 16(9); 1361-72. ©2018 AACR.
Collapse
Affiliation(s)
- Michael J Bond
- Department of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut.,Department of Pharmacology, Yale University, New Haven, Connecticut
| | - Marina Bleiler
- Department of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut
| | - Lauren E Harrison
- Department of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut
| | - Eric W Scocchera
- Department of Medicinal Chemistry, University of Connecticut, Storrs, Connecticut
| | - Masako Nakanishi
- Center for Molecular Oncology, UConn Health, Farmington, Connecticut
| | - Narendran G-Dayanan
- Department of Medicinal Chemistry, University of Connecticut, Storrs, Connecticut
| | - Santosh Keshipeddy
- Department of Medicinal Chemistry, University of Connecticut, Storrs, Connecticut
| | | | - Dennis L Wright
- Department of Medicinal Chemistry, University of Connecticut, Storrs, Connecticut
| | - Charles Giardina
- Department of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut.
| |
Collapse
|
20
|
Mangiatordi GF, Trisciuzzi D, Iacobazzi R, Denora N, Pisani L, Catto M, Leonetti F, Alberga D, Nicolotti O. Automated identification of structurally heterogeneous and patentable antiproliferative hits as potential tubulin inhibitors. Chem Biol Drug Des 2018; 92:1161-1170. [PMID: 29633572 DOI: 10.1111/cbdd.13200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Revised: 02/05/2018] [Accepted: 03/03/2018] [Indexed: 12/27/2022]
Abstract
By employing a recently developed hierarchical computational platform, we identified 37 novel and structurally diverse tubulin targeting compounds. In particular, hierarchical molecular filters, based on molecular shape similarity, structure-based pharmacophore, and molecular docking, were applied on a large chemical collection of commercial compounds to identify unexplored and patentable microtubule-destabilizing candidates. The herein proposed 37 novel hits, showing new molecular scaffolds (such as 1,3,3a,4-tetraaza-1,2,3,4,5,6,7,7a-octahydroindene or dihydropyrrolidin-2-one fused to a chromen-4-one), are provided with antiproliferative activity in the μm range toward MCF-7 (human breast cancer lines). Importantly, there is a likely causative relationship between cytotoxicity and the inhibition of tubulin polymerization at the colchicine binding site, assessed through fluorescence polymerization assays.
Collapse
Affiliation(s)
| | - Daniela Trisciuzzi
- Dipartimento di Farmacia-Scienze del Farmaco, Università di Bari 'Aldo Moro', Bari, Italy
| | | | - Nunzio Denora
- Dipartimento di Farmacia-Scienze del Farmaco, Università di Bari 'Aldo Moro', Bari, Italy
| | - Leonardo Pisani
- Dipartimento di Farmacia-Scienze del Farmaco, Università di Bari 'Aldo Moro', Bari, Italy
| | - Marco Catto
- Dipartimento di Farmacia-Scienze del Farmaco, Università di Bari 'Aldo Moro', Bari, Italy
| | - Francesco Leonetti
- Dipartimento di Farmacia-Scienze del Farmaco, Università di Bari 'Aldo Moro', Bari, Italy
| | - Domenico Alberga
- Dipartimento di Farmacia-Scienze del Farmaco, Università di Bari 'Aldo Moro', Bari, Italy
| | - Orazio Nicolotti
- Dipartimento di Farmacia-Scienze del Farmaco, Università di Bari 'Aldo Moro', Bari, Italy
| |
Collapse
|
21
|
Argyros O, Karampelas T, Varela A, Asvos X, Papakyriakou A, Agalou A, Beis D, Davos CH, Fokas D, Tamvakopoulos C. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule. Oncotarget 2018; 8:37250-37262. [PMID: 28422745 PMCID: PMC5514907 DOI: 10.18632/oncotarget.16763] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 03/22/2017] [Indexed: 01/11/2023] Open
Abstract
The clinical efficacy of antiangiogenic small molecules (e.g., sunitinib) in breast carcinoma has largely failed with substantial off-target toxicity. We rationally designed and evaluated preclinically a novel sunitinib analogue, SAP, with favourable pharmacological properties and the ability to be readily conjugated to a targeting peptide or antibody for active tumour targeting. SAP was evaluated in silico and in vitro in order to verify target engagement (e.g., VEGFR2). Pharmacokinetic and biodistribution parameters were determined in mice using LC-MS/MS. SAP efficacy was tested in two breast cancer xenograft and two syngeneic animal models and pharmacodynamic evaluation was accomplished using phosphokinase assays and immunohistochemistry. Cardiac and blood toxicity of SAP were also monitored. SAP retained the antiangiogenic and cytotoxic properties of the parental molecule with an increased blood exposure and tumor accumulation compared to sunitinib. SAP proved efficacious in all animal models. Tumors from SAP treated animals had significantly decreased Ki-67 and CD31 markers and reduced levels of phosphorylated AKT, ERK and S6 compared to vehicle treated animals. In mice dosed with SAP there was negligible hematotoxicity, while cardiac function measurements showed a reduction in the percentage left ventricular fractional shortening compared to vehicle treated animals. In conclusion, SAP is a novel rationally designed conjugatable small antiangiogenic molecule, efficacious in preclinical models of breast cancer.
Collapse
Affiliation(s)
- Orestis Argyros
- Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation Academy of Athens, Athens, 11527, Greece
| | - Theodoros Karampelas
- Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation Academy of Athens, Athens, 11527, Greece
| | - Aimilia Varela
- Cardiovascular Research Laboratory, Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation Academy of Athens, Athens, 11527, Greece
| | - Xenophon Asvos
- Laboratory of Medicinal Chemistry, Department of Materials Science and Engineering, University of Ioannina, Ioannina, 45110, Greece
| | - Athanasios Papakyriakou
- Laboratory of Chemical Biology of Natural Products and Designed Molecules, Institute of Physical Chemistry, N.C.S.R "Demokritos", Athens, 15310, Greece
| | - Adamantia Agalou
- Developmental Biology, Biomedical Research Foundation Academy of Athens, Athens, 11527, Greece
| | - Dimitris Beis
- Developmental Biology, Biomedical Research Foundation Academy of Athens, Athens, 11527, Greece
| | - Constantinos H Davos
- Cardiovascular Research Laboratory, Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation Academy of Athens, Athens, 11527, Greece
| | - Demosthenes Fokas
- Laboratory of Medicinal Chemistry, Department of Materials Science and Engineering, University of Ioannina, Ioannina, 45110, Greece
| | - Constantin Tamvakopoulos
- Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation Academy of Athens, Athens, 11527, Greece
| |
Collapse
|
22
|
In silico binding affinity studies of N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives-Target for P70-S6K1 & PI3K-δ kinases. BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES 2018. [DOI: 10.1016/j.bjbas.2017.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
23
|
Yousuf I, Usman M, Ahmad M, Tabassum S, Arjmand F. Single X-ray crystal structure, DFT studies and topoisomerase I inhibition activity of a tailored ionic Ag( i) nalidixic acid–piperazinium drug entity specific for pancreatic cancer cells. NEW J CHEM 2018; 42:506-519. [DOI: 10.1039/c7nj03602g] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/12/2023]
Abstract
DFT studies, Topo I inhibition assay and cytotoxic activity of novel ionic Ag(i) nalidixic acid–piperazinium molecular entity.
Collapse
Affiliation(s)
- Imtiyaz Yousuf
- Department of Chemistry
- Aligarh Muslim University
- Aligarh 202002
- India
| | - Mohammad Usman
- Department of Chemistry
- Aligarh Muslim University
- Aligarh 202002
- India
| | - Musheer Ahmad
- Department of Applied Chemistry
- Aligarh Muslim University
- Aligarh 202002
- India
| | - Sartaj Tabassum
- Department of Chemistry
- Aligarh Muslim University
- Aligarh 202002
- India
| | - Farukh Arjmand
- Department of Chemistry
- Aligarh Muslim University
- Aligarh 202002
- India
| |
Collapse
|
24
|
Wu Y, Feng D, Gao M, Wang Z, Yan P, Gu Z, Guan Q, Zuo D, Bao K, Sun J, Wu Y, Zhang W. Design and synthesis of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2H-1,2,3-triazole derivatives as colchicine binding site inhibitors. Sci Rep 2017; 7:17120. [PMID: 29215079 PMCID: PMC5719359 DOI: 10.1038/s41598-017-17449-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Accepted: 11/27/2017] [Indexed: 11/09/2022] Open
Abstract
A series of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2H-1,2,3-triazol derivatives were designed as potential microtubule targeting agents. The regioselective alkylation of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2H-1,2,3-triazole was predicted by computations and confirmed by an unambiguous synthetic route. The antiproliferative activity of the synthesized compounds was tested in vitro using three human cancer cell lines and some compounds exhibited significant antiproliferative activity, which suggested the reasonability of introduction of the 1,2,3-triazole fragment. Among them, compound 7p showed highest activity with the IC50 values at nanomolar level towards all three cell lines, which were comparable to the positive control, CA-4. Tubulin polymerization assay, immunofluorescence studies, cell cycle analysis and competitive tubulin-binding assay strongly proved that 7p is a colchicine binding site inhibitor of tubulin. Thus, 7p was identified as a promising drug candidate for further development of colchicine binding site inhibitors.
Collapse
Affiliation(s)
- Yue Wu
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Dongjie Feng
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Meiqi Gao
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Zhiwei Wang
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Peng Yan
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Zhenzhen Gu
- Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Qi Guan
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Daiying Zuo
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Kai Bao
- Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China
| | - Jun Sun
- Clinical Pharmacology Laboratory, Henan Province People's Hospital, Zhengzhou University People's Hospital, 7 Weiwu Road, Jinshui District, Zhengzhou, 450003, China.
| | - Yingliang Wu
- Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.
| | - Weige Zhang
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.
| |
Collapse
|
25
|
Olazarán FE, García-Pérez CA, Bandyopadhyay D, Balderas-Rentería I, Reyes-Figueroa AD, Henschke L, Rivera G. Theoretical and experimental study of polycyclic aromatic compounds as β-tubulin inhibitors. J Mol Model 2017; 23:85. [PMID: 28214932 DOI: 10.1007/s00894-017-3256-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Accepted: 01/23/2017] [Indexed: 12/14/2022]
Abstract
In this work, through a docking analysis of compounds from the ZINC chemical library on human β-tubulin using high performance computer cluster, we report new polycyclic aromatic compounds that bind with high energy on the colchicine binding site of β-tubulin, suggesting three new key amino acids. However, molecular dynamic analysis showed low stability in the interaction between ligand and receptor. Results were confirmed experimentally in in vitro and in vivo models that suggest that molecular dynamics simulation is the best option to find new potential β-tubulin inhibitors. Graphical abstract Bennett's acceptance ratio (BAR) method.
Collapse
Affiliation(s)
- Fabian E Olazarán
- Facultad de Ciencias Químicas. Av. Universidad s/n, Ciudad Universitaria, San Nicolás de los Garza, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, 64451, México
| | - Carlos A García-Pérez
- Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Boulevard del Maestro, s/n, Esq. Elías Piña, Reynosa, Tamualipas, Mexico, 88710
| | - Debasish Bandyopadhyay
- Department of Chemistry, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX, 78539, USA
| | - Isaias Balderas-Rentería
- Facultad de Ciencias Químicas. Av. Universidad s/n, Ciudad Universitaria, San Nicolás de los Garza, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, 64451, México
| | - Angel D Reyes-Figueroa
- Centro de Investigación y de Estudios Avanzados del Instituto Politecnico Nacional, Unidad Monterrey, Apodaca, Nuevo León, 66600, México
| | - Lars Henschke
- Department of Biology, University of Konstanz, Universitätsstraβe 10, 78457, Konstanz, Germany
| | - Gildardo Rivera
- Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Boulevard del Maestro, s/n, Esq. Elías Piña, Reynosa, Tamualipas, Mexico, 88710.
| |
Collapse
|
26
|
Prinz H, Ridder AK, Vogel K, Böhm KJ, Ivanov I, Ghasemi JB, Aghaee E, Müller K. N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization. J Med Chem 2017; 60:749-766. [PMID: 28045256 DOI: 10.1021/acs.jmedchem.6b01591] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
We report here a series of 27 10-(4-phenylpiperazin-1-yl)methanones derived from tricyclic heterocycles which were screened for effects on tumor cell growth, inhibition of tubulin polymerization, and induction of cell cycle arrest. Several analogues, among them the 10-(4-(3-methoxyphenyl)piperazine-1-carbonyl)-10H-phenoxazine-3-carbonitrile (16o), showed excellent antiproliferative properties, with low nanomolar GI50 values (16o, mean GI50 of 3.3 nM) against a large number (93) of cancer cell lines. Fifteen compounds potently inhibited tubulin polymerization. Analysis of cell cycle by flow cytometry revealed that inhibition of tumor cell growth was related to an induction of G2/M phase cell cycle blockade. Western blotting and molecular docking studies suggested that these compounds bind efficiently to β-tubulin at the colchicine binding site. Our studies demonstrate the suitability of the phenoxazine and phenothiazine core and also of the phenylpiperazine moiety for the development of novel and potent tubulin polymerization inhibitors.
Collapse
Affiliation(s)
- Helge Prinz
- Institute of Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University , Corrensstraße 48, D-48149 Münster, Germany
| | - Ann-Kathrin Ridder
- Institute of Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University , Corrensstraße 48, D-48149 Münster, Germany
| | - Kirsten Vogel
- Institute of Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University , Corrensstraße 48, D-48149 Münster, Germany
| | - Konrad J Böhm
- Leibniz Institute on Aging-Fritz Lipmann Institute (FLI) , Beutenbergstrasse 11, D-07745 Jena, Germany
| | - Igor Ivanov
- Oncolead GmbH & Co. KG , Zugspitzstraße 5, D-85757 Karlsfeld, Germany
| | - Jahan B Ghasemi
- Drug Design in Silico Lab, Chemistry Faculty, School of Sciences, University of Tehran , Teheran, Iran
| | - Elham Aghaee
- Drug Design in Silico Lab, Chemistry Faculty, School of Sciences, University of Tehran , Teheran, Iran
| | - Klaus Müller
- Institute of Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University , Corrensstraße 48, D-48149 Münster, Germany
| |
Collapse
|
27
|
SINGH ANILK, BHARDWAJ JITENDERK, OLIVAL ANA, KUMAR YOGESH, PODDER AVIJIT, MAHESHWARI ANKUR, AGRAWAL RENUKA, LATHA N, SINGH BRAJENDRAK, TOMÁS HELENA, RODRIGUES JOÃO, KISHAN RAM, RUPINI B, RATHI BRIJESH. Design, synthesis and biological evaluation of Arylpiperazine-based novel Phthalimides: Active inducers of testicular germ cell apoptosis. J CHEM SCI 2016. [DOI: 10.1007/s12039-016-1122-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
28
|
Efficient Activation of Apoptotic Signaling during Mitotic Arrest with AK301. PLoS One 2016; 11:e0153818. [PMID: 27097159 PMCID: PMC4838221 DOI: 10.1371/journal.pone.0153818] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Accepted: 04/04/2016] [Indexed: 12/20/2022] Open
Abstract
Mitotic inhibitors are widely utilized chemotherapeutic agents that take advantage of mitotic defects in cancer cells. We have identified a novel class of piperazine-based mitotic inhibitors, of which AK301 is the most potent derivative identified to date (EC50 < 200 nM). Colon cancer cells arrested in mitosis with AK301 readily underwent a p53-dependent apoptosis following compound withdrawal and arrest release. This apoptotic response was significantly higher for AK301 than for other mitotic inhibitors tested (colchicine, vincristine, and BI 2536). AK301-treated cells exhibited a robust mitosis-associated DNA damage response, including ATM activation, γH2AX phosphorylation and p53 stabilization. The association between mitotic signaling and the DNA damage response was supported by the finding that Aurora B inhibition reduced the level of γH2AX staining. Confocal imaging of AK301-treated cells revealed multiple γ-tubulin microtubule organizing centers attached to microtubules, but with limited centrosome migration, raising the possibility that aberrant microtubule pulling may underlie DNA breakage. AK301 selectively targeted APC-mutant colonocytes and promoted TNF-induced apoptosis in p53-mutant colon cancer cells. Our findings indicate that AK301 induces a mitotic arrest state with a highly active DNA damage response. Together with a reversible arrest state, AK301 is a potent promoter of a mitosis-to-apoptosis transition that can target cancer cells with mitotic defects.
Collapse
|
29
|
Man RJ, Tang DJ, Lu XY, Duan YT, Tao XX, Yang MR, Wang LL, Wang BZ, Xu C, Zhu HL. Synthesis and biological evaluation of novel indole derivatives containing sulfonamide scaffold as potential tubulin inhibitor. MEDCHEMCOMM 2016. [DOI: 10.1039/c6md00255b] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Microtubule-targeted drugs play a critical role in various types of cancer therapy worldwide.
Collapse
Affiliation(s)
- Ruo-Jun Man
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
- Guangxi University for Nationalities
| | - Dan-Jie Tang
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Xiao-Yuan Lu
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Yong-Tao Duan
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Xiang-Xiang Tao
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Meng-Ru Yang
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Le-Le Wang
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Bao-Zhong Wang
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Chen Xu
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| | - Hai-Liang Zhu
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210023
- People's Republic of China
| |
Collapse
|
30
|
Sunagar MG, Gaonkar S, Sunagar SG, Deshapande N, Belavagi NS, Khazi IAM. Synthesis of novel N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives as inducers of apoptosis in MCF-7 breast cancer cells. RSC Adv 2016. [DOI: 10.1039/c5ra23242b] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series of N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives (PP05–PP21) were prepared and evaluated for their anticancer activity against a panel of human cancer cell lines.
Collapse
Affiliation(s)
| | - Supreet Gaonkar
- Department of Chemistry
- Karnatak University
- Dharwad 580003
- India
| | - Santosh G. Sunagar
- Bio-X Institutes
- Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education)
- Shanghai Jiao Tong University
- Shanghai 200240
- P. R. China
| | | | | | | |
Collapse
|
31
|
Kuo MC, Chang SJ, Hsieh MC. Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: A 12-Year Cohort Study. Medicine (Baltimore) 2015; 94:e1570. [PMID: 26683907 PMCID: PMC5058879 DOI: 10.1097/md.0000000000001570] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Patients with gout are more likely to develop most cancers than subjects without gout. Colchicine has been used for the treatment and prevention of gouty arthritis and has been reported to have an anticancer effect in vitro. However, to date no study has evaluated the relationship between colchicine use and incident cancers in patients with gout. This study enrolled male patients with gout identified in Taiwan's National Health Insurance Database for the years 1998 to 2011. Each gout patient was matched with 4 male controls by age and by month and year of first diagnosis, and was followed up until 2011. The study excluded those who were diagnosed with diabetes or any type of cancer within the year following enrollment. We calculated hazard ratio (HR), aged-adjusted standardized incidence ratio, and incidence of 1000 person-years analyses to evaluate cancer risk. A total of 24,050 male patients with gout and 76,129 male nongout controls were included. Patients with gout had a higher rate of incident all-cause cancers than controls (6.68% vs 6.43%, P = 0.006). A total of 13,679 patients with gout were defined as having been ever-users of colchicine and 10,371 patients with gout were defined as being never-users of colchicine. Ever-users of colchicine had a significantly lower HR of incident all-cause cancers than never-users of colchicine after adjustment for age (HR = 0.85, 95% CI = 0.77-0.94; P = 0.001). In conclusion, colchicine use was associated with a decreased risk of incident all-cause cancers in male Taiwanese patients with gout.
Collapse
Affiliation(s)
- Ming-Chun Kuo
- From the Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung (M-CK); Chang Gung University College of Medicine (M-CK); National University of Kaohsiung, Kaohsiung (S-JC); Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua (M-CH); and Graduate Institute of Integrated Medicine, China Medical University, Taiwan (M-CH)
| | | | | |
Collapse
|
32
|
HUANG ZHEN, XU YE, PENG WEI. Colchicine induces apoptosis in HT-29 human colon cancer cells via the AKT and c-Jun N-terminal kinase signaling pathways. Mol Med Rep 2015; 12:5939-44. [DOI: 10.3892/mmr.2015.4222] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2014] [Accepted: 06/05/2015] [Indexed: 11/06/2022] Open
|
33
|
Voitovich YV, Shegravina ES, Sitnikov NS, Faerman VI, Fokin VV, Schmalz HG, Combes S, Allegro D, Barbier P, Beletskaya IP, Svirshchevskaya EV, Fedorov AY. Synthesis and Biological Evaluation of Furanoallocolchicinoids. J Med Chem 2014; 58:692-704. [DOI: 10.1021/jm501678w] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Yuliya V. Voitovich
- Department
of Organic Chemistry, Nizhny Novgorod State University, Gagarina
av. 23, Nizhny Novgorod 603950, Russian Federation
| | - Ekaterina S. Shegravina
- Department
of Organic Chemistry, Nizhny Novgorod State University, Gagarina
av. 23, Nizhny Novgorod 603950, Russian Federation
| | - Nikolay S. Sitnikov
- Department
of Organic Chemistry, Nizhny Novgorod State University, Gagarina
av. 23, Nizhny Novgorod 603950, Russian Federation
| | - Vladimir I. Faerman
- Department
of Organic Chemistry, Nizhny Novgorod State University, Gagarina
av. 23, Nizhny Novgorod 603950, Russian Federation
| | - Valery V. Fokin
- Department
of Organic Chemistry, Nizhny Novgorod State University, Gagarina
av. 23, Nizhny Novgorod 603950, Russian Federation
| | - Hans-Gunther Schmalz
- Department
of Chemistry, University of Cologne, Greinstrasse 4, 50939 Koln, Germany
| | - Sebastien Combes
- CRCM,
CNRS UMR7258, Laboratory of Integrative Structural and Chemical Biology
(ISCB), INSERM, U1068, Institut Paoli-Calmettes, Aix-Marseille Universit́e, UM105,
F-13009, Marseille, France
| | - Diane Allegro
- Centre de Recherche en Oncologie Biologique et en Oncopharmacologie,
CRO2 INSERM UMR 911, Faculte de Pharmacie, Universite d’Aix-Marseille, 27 Boulevard Jean Moulin, Marseille 13005, France
| | - Pascal Barbier
- Centre de Recherche en Oncologie Biologique et en Oncopharmacologie,
CRO2 INSERM UMR 911, Faculte de Pharmacie, Universite d’Aix-Marseille, 27 Boulevard Jean Moulin, Marseille 13005, France
| | - Irina P. Beletskaya
- Department
of Chemistry, M.V. Lomonosov Moscow State University, Vorobyevy Gory, 119992 Moscow, Russian Federation
| | - Elena V. Svirshchevskaya
- Laboratory
of Cell Interactions, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, GSP-7, Miklukho-Maklaya Street, 16/10, 117997 Moscow, Russian Federation
| | - Alexey Yu. Fedorov
- Department
of Organic Chemistry, Nizhny Novgorod State University, Gagarina
av. 23, Nizhny Novgorod 603950, Russian Federation
| |
Collapse
|